Author

V. Valero

Observed names: V Valero, Valero, Vincente, Vincente V. Valero, Vincente Valero

Observed institutions: University of Modena and Reggio Emilia, Brigham and Women's Hospital, Fox Chase Cancer Center, The University of Texas MD Anderson Cancer Center, University of Miami, Okayama University, Institut Jules Bordet, Yale Cancer Center, Yale University, Bristol-Myers Squibb (United States), Guardant (United States), Nuvera Biosciences (United States), AstraZeneca (United States), Dana-Farber Brigham Cancer Center, Huron University, Takeda Oncology (United States), University of Cincinnati, Comenius University Bratislava, Charité - Universitätsmedizin Berlin

OpenAlex ID: A5085392017

Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy

2008 · Abenaa M. Brewster, Gabriel N. Hortobagyi, et al. · JNCI Journal of the National Cancer Institute · 331

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

2022 · Sang T. Kim, Yanshuo Chu, et al. · Nature Communications · 116

Clinical outcome of patients with lymph node‐negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry

2005 · Anees Chagpar, Lavinia P. Middleton, et al. · Cancer · 107

Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer

2009 · U. De Giorgi, V. Valero, et al. · Annals of Oncology · 84

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

2020 · Anthony W. Tolcher, Razelle Kurzrock, et al. · Cancer Chemotherapy and Pharmacology · 56

Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer

2014 · Chelsea G. Ratcliff, Cho Y. Lam, et al. · Psycho-Oncology · 53

Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.

2003 · Darren W Davis, Thomas A Buchholz, et al. · PubMed · 52

A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

2008 · M. Cristofanilli, V. Valero, et al. · Journal of Clinical Oncology · 43

Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy

1998 · E.A. Diaz-Canton, V. Valero, et al. · Annals of Oncology · 36

Mesenteric laceration complicating a heimlich maneuver

1986 · Vincente Valero · Annals of Emergency Medicine · 35

Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.

1995 · K Dhingra, H Fritsche, et al. · PubMed · 23

Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors.

2009 · R Rakkhit, K Broglio, et al. · Cancer Research · 20

Abstract S6-02: Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy

2013 · WF Symmans, C Wei, et al. · Cancer Research · 12

Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC)

2009 · M. Cristofanilli, R. Schiff, et al. · Journal of Clinical Oncology · 12

Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites.

2010 · A. Giordano, M. Giuliano, et al. · Journal of Clinical Oncology · 10

Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial)

2020 · Kathryn J. Ruddy, Lorenzo Trippa, et al. · Cancer Research · 9

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression

2013 · M. Chavez-MacGregor, V. Valero · Breast Diseases A Year Book Quarterly · 9

A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy

2006 · W. Symmans, F. Peintinger, et al. · Journal of Clinical Oncology · 8

Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer.

2011 · A. Giordano, M. Mego, et al. · Journal of Clinical Oncology · 7

Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel

2006 · S. R. Amin, V. Valero, et al. · Journal of Clinical Oncology · 5

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy.

2010 · M. Giuliano, A. Giordano, et al. · Journal of Clinical Oncology · 4

A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)

2025 · Maeve A. Hennessy, Ashley Cimino-Mathews, et al. · The Breast · 3

Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs

2023 · Zijian Zhou, Beatriz E. Adrada, et al. · Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society · 3

Taxanes in metastatic breast cancer patients with impaired liver function

2005 · L. B. Michaud, E. Rivera, et al. · Journal of Clinical Oncology · 3

Treatment of patients resistant to paclitaxel therapy

1996 · V Valero · Anti-Cancer Drugs · 3

Works count: 68

Citation count: 1,064

H-index: 12

I10-index: 15